Iceland

Speaking exclusively to Generics Bulletin, Alvotech’s founder Robert Wessman explains why the company’s leadership split and Lisa Graver’s Iceland-based appointment as CEO mark a pivotal moment in its operational evolution.

What exactly is causing Alvotech’s frustrating list of US complete response letters? In a recent call with investors, management shed light on the company’s issues.

Alvotech has unveiled a planned leadership transition, with founder and chairman Róbert Wessman handing the chief executive role to long-time collaborator Lisa Graver as the biosimilars specialist prepares for its next phase of growth.

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Drug companies are being invited to participate in a new pilot project that the five Nordic countries will run to see if they can improve the availability of certain critical products that are used in hospitals.

European cross-country HTA collaborations have much to learn from each other to keep prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.

European cross-country HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.

It is time for companies to take part in cross-country health technology assessments and stop only asking “what’s in it for me?”

It is time for companies to take part in cross-country health technology assessments and stop asking “what’s in it for me?”

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Scotland’s health technology assessment body has agreed to reimburse Chiesi’s Elfabrio for Fabry disease, mirroring the decision from several other European countries – however, France turned down the rare disease drug, while Germany questioned its benefit.